“Epidermal Growth Factor Receptor + Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the EGFR Non-Small Cell Lung Cancer Market.
The EGFR Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Epidermal Growth Factor Receptor + Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of EGFR Non-Small Cell Lung Cancer and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the EGFR Non-Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Learn How the Ongoing Clinical & Commercial Activities will Affect the EGFR Non-Small Cell Lung Cancer Therapeutic Segment @
EGFR Non-Small Cell Lung Cancer Therapeutics Landscape
There are approx. 30+ key companies developing therapies for EGFR Non-Small Cell Lung Cancer. AstraZeneca, Betta Pharmaceuticals, Millennium Pharmaceuticals, and Takeda are some of the leading companies with their EGFR Non-Small Cell Lung Cancer drug candidates in the advanced stage of clinical development.
The Leading Companies in the EGFR Non-Small Cell Lung Cancer Therapeutics Market Include:
Betta Pharmaceuticals Co., Ltd.
Hangzhou ACEA Pharmaceutical Research
G1 Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Allist Pharmaceuticals, Inc.
And Many Others
EGFR Non-Small Cell Lung Cancer Emerging and Marketed Drugs Covered in the Report Include:
DZD9008: Dizal Pharmaceuticals
Nazartinib (EGF816) – Novartis Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. EGFR Non-Small Cell Lung Cancer Current Treatment Patterns
4. EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. EGFR Non-Small Cell Lung Cancer Late Stage Products (Phase-III)
7. EGFR Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. EGFR Non-Small Cell Lung Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. EGFR Non-Small Cell Lung Cancer Discontinued Products
13. EGFR Non-Small Cell Lung Cancer Product Profiles
14. Key Companies in the EGFR Non-Small Cell Lung Cancer Market
15. Key Products in the EGFR Non-Small Cell Lung Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. EGFR Non-Small Cell Lung Cancer Unmet Needs
18. EGFR Non-Small Cell Lung Cancer Future Perspectives
19. EGFR Non-Small Cell Lung Cancer Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Nephrosclerosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nephrosclerosis market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Nephrosclerosis market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States